Exact Sciences (EXAS) Expected to Announce Quarterly Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is expected to post its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Exact Sciences to post earnings of ($0.29) per share and revenue of $701.45 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Exact Sciences Stock Performance

Exact Sciences stock opened at $51.06 on Wednesday. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The business’s 50-day moving average price is $56.93 and its two-hundred day moving average price is $60.20. The stock has a market cap of $9.45 billion, a PE ratio of -43.64 and a beta of 1.24.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. BTIG Research lifted their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus decreased their target price on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group decreased their target price on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler decreased their target price on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, The Goldman Sachs Group reduced their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.